Diaceutics PLC Cancellation of Share Premium Account
24 Ottobre 2024 - 1:53PM
RNS Regulatory News
RNS Number : 5086J
Diaceutics PLC
24 October 2024
24 October 2024
Diaceutics plc
(the
"Company")
Cancellation of Share Premium
Account
Belfast and London, 24 October
2024 - Diaceutics PLC (AIM: DXRX), a leading technology and
solutions provider to the pharma and biotech industry, is pleased
to announce that earlier today the High Court of Justice in
Northern Ireland confirmed the cancellation of the sum standing to
the credit of the Company's share premium account (the "Reduction
of Capital"). The Reduction of Capital will become effective on
registration of the Court order at Companies House, which is
expected to occur in the next few days.
The Reduction of Capital, as
described in the AGM Notice that was sent to shareholders on 29 May
2024 and which is available on the Company's website
(https://investors.diaceutics.com), was approved by way of a
special resolution passed by the shareholders of the Company at the
annual general meeting held on 24 June 2024.
The purpose of the Reduction of
Capital is to create distributable reserves which will provide the
Company with flexibility to support, amongst other things, share
buy-backs, the funding of the Company's share option schemes and
the payment of dividends or other distributions to shareholders in
the future.
|
Enquiries:
|
|
|
|
|
|
Diaceutics PLC
|
Tel: +44 (0)28 9040 6500
|
|
Ryan Keeling, Chief Executive
Officer
|
investorrelations@diaceutics.com
|
|
Nick Roberts, Chief Financial
Officer
|
|
|
Canaccord Genuity Limited (Nomad
& Broker)
|
Tel: +44 (0)20 7523 8000
|
|
Simon Bridges, Andrew Potts, Harry
Rees
|
|
|
Alma Strategic
Communications
|
Tel: +44(0)20 3405 0205
|
|
Caroline Forde, Kinvara
Verdon
|
diaceutics@almastrategic.com
|
About Diaceutics
At Diaceutics we believe that every
patient should get the opportunity to receive the right test and
the right therapy to positively impact their disease outcome. We
provide the world's leading pharma and biotech companies with an
end-to-end commercialisation solution for precision medicines
through data analytics, scientific and advisory services enabled by
our platform DXRX - The Diagnostics Network®.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCQKQBQDBDDAKB
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Diaceutics (LSE:DXRX)
Storico
Da Nov 2023 a Nov 2024
